Table 1. Associations between patient-reported physical function and ECOG-PS with OS for patients treated with atezolizumab.
| Parameter | Univariable | Multivariable# | ||||||
|---|---|---|---|---|---|---|---|---|
| n | HR [95% CI] | P | c | n | HR [95% CI] | P | ||
| Physical function | <0.001 | 0.60 | <0.001 | |||||
| Low | 270 | 2.75 [2.23 to 3.40] | 270 | 2.38 [1.92 to 2.95] | ||||
| Intermediate | 1,013 | 1.59 [1.33 to 1.89] | 1,010 | 1.49 [1.25 to 1.78] | ||||
| High | 458 | 1 | 456 | 1 | ||||
| ECOG-PS | <0.001 | 0.57 | <0.001 | |||||
| 0 | 761 | 1 | 671 | |||||
| 1+ | 1,166 | 1.72 [1.50 to 1.97] | 1,065 | 1.53 [1.32 to 1.78] | ||||
#, model includes pre-treatment physical function and ECOG-PS. CI, confidence interval; c, c-statistic; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; n, number.